Jan. 29/2013 – Lung and Colon Cancer Research Trial
As part of Aim Medical Imaging’s commitment to advancing state-of-the-art diagnostic imaging in Canada, we are pleased to announce a new phase of research into early cancer diagnosis.
In United States and abroad, patients who are suspected of having cancer are provided with a staging functional imaging test (usually PETCT), which is used as a baseline to monitor the response to cancer treatment. Unfortunately, this baseline study is not routinely performed in BC, and thus assessing response to treatment can be delayed, or is unknown.
At Aim, we are seeing patient’s suspected of having lung, and colon cancer to participate in our research study. If eligible, these patients will be offered a state-of-the-art whole body MRI, and staging PETCT.
Dec. 15/2012 – We are currently working with a pharmaceutical company investigating the utilisation of MRI for Crohn’s Disease research and follow up. At this preliminary stage our imaging techniques appear to be extremely robust and, unlike CT, avoids the use of ionisating radiation.
We are also investigating the positive and negative aspects of performing MRI with a continuous moving table. There are very few machines with this capability worldwide. If we can demonstrate MRI has superior lesion detection to to CT with a similar scan time with this technique, then we may be able to shift the routine imaging away from CT for the sake of patient care.
Nov. 19/2010 – Diffusion-weighted magnetic resonance imaging (DWI) provides functional information and can be used for the detection and characterization of pathologic processes, including malignant tumors. Cancer is the second leading cause of death in developed countries, is among the three leading causes of death for adults in developing countries, and is responsible for many deaths worldwide.